Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTOR Citius Oncology	$2.12 +1.4%	$2.51	$0.55 ▼ $6.19	$163.79M	3	269,616 shs	211,875 shs
FATE Fate Therapeutics	$1.08 -3.6%	$1.12	$0.66 ▼ $4.20	$129.17M	2.24	1.50 million shs	755,501 shs
HYPD Hyperion DeFi	$6.63 -3.9%	$9.48	$0.85 ▼ $52.00	$39.29M	2.42	532,493 shs	351,996 shs
SCLX Scilex	$18.23 +1.2%	$11.68	$3.60 ▼ $42.53	$125.34M	1.32	262,414 shs	108,879 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTOR Citius Oncology	+5.03%	+29.81%	+11.76%	+134.75%	+14.21%
FATE Fate Therapeutics	+0.90%	-0.88%	-13.85%	-15.15%	-68.80%
HYPD Hyperion DeFi	-1.15%	+11.11%	-27.37%	+281.22%	-84.87%
SCLX Scilex	0.00%	+2.56%	+16.11%	+218.94%	-54.03%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTOR Citius Oncology	1.3993 of 5 stars	3.0	0.0	0.0	2.2	1.7	0.0
FATE Fate Therapeutics	3.9764 of 5 stars	3.1	2.0	4.7	1.9	2.5	0.6
HYPD Hyperion DeFi	0.3583 of 5 stars	1.0	0.0	0.0	2.8	0.8	0.6
SCLX Scilex	2.2382 of 5 stars	3.3	2.0	0.0	2.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTOR Citius Oncology	2.00	Hold	$3.00	41.51% Upside
FATE Fate Therapeutics	2.14	Hold	$3.30	205.56% Upside
HYPD Hyperion DeFi	2.00	Hold	$2.00	-69.83% Downside
SCLX Scilex	2.50	Moderate Buy	$455.00	2,395.89% Upside

Current Analyst Ratings Breakdown

Latest HYPD, CTOR, FATE, and SCLX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/13/2025	FATE Fate Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$4.00 ➝ $2.50
6/12/2025	FATE Fate Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTOR Citius Oncology	N/A	N/A	N/A	N/A	$0.41 per share	N/A
FATE Fate Therapeutics	$13.63M	9.14	N/A	N/A	$2.27 per share	0.48
HYPD Hyperion DeFi	$60K	628.75	N/A	N/A	$6.56 per share	1.01
SCLX Scilex	$56.59M	2.24	N/A	N/A	($35.80) per share	-0.51

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTOR Citius Oncology	N/A	N/A	0.00	∞	N/A	N/A	-51.93%	-22.17%	N/A
FATE Fate Therapeutics	-$186.26M	-$1.45	N/A	N/A	N/A	-2,025.05%	-50.95%	-36.76%	11/11/2025 (Estimated)
HYPD Hyperion DeFi	-$49.82M	-$58.40	0.00	N/A	N/A	-62,238.41%	-876.25%	-181.67%	N/A
SCLX Scilex	-$72.81M	-$29.02	N/A	N/A	N/A	-179.12%	N/A	-109.95%	11/12/2025 (Estimated)

Latest HYPD, CTOR, FATE, and SCLX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	HYPD Hyperion DeFi	N/A	-$2.50	N/A	-$2.50	N/A	N/A
8/13/2025	Q2 2025	SCLX Scilex	-$4.55	-$7.42	-$2.87	-$7.42	$26.25 million	$9.90 million
8/12/2025	Q2 2025	FATE Fate Therapeutics	-$0.35	-$0.29	+$0.06	-$0.29	$1.16 million	$1.91 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTOR Citius Oncology	N/A	N/A	N/A	N/A	N/A
FATE Fate Therapeutics	N/A	N/A	N/A	N/A	N/A
HYPD Hyperion DeFi	N/A	N/A	N/A	N/A	N/A
SCLX Scilex	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTOR Citius Oncology	0.12	0.35	0.02
FATE Fate Therapeutics	N/A	8.04	8.04
HYPD Hyperion DeFi	0.20	0.91	0.91
SCLX Scilex	N/A	0.11	0.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTOR Citius Oncology	70.52%
FATE Fate Therapeutics	97.54%
HYPD Hyperion DeFi	25.84%
SCLX Scilex	69.67%

Insider Ownership

Company	Insider Ownership
CTOR Citius Oncology	4.57%
FATE Fate Therapeutics	5.51%
HYPD Hyperion DeFi	10.86%
SCLX Scilex	7.94%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTOR Citius Oncology	N/A	78.37 million	74.79 million	N/A
FATE Fate Therapeutics	550	115.33 million	108.98 million	Optionable
HYPD Hyperion DeFi	40	5.69 million	5.08 million	No Data
SCLX Scilex	80	6.96 million	6.40 million	Optionable

HYPD, CTOR, FATE, and SCLX Headlines

Recent News About These Companies

Scilex (NASDAQ:SCLX) Trading Up 10.1% - Time to Buy?

August 25 at 4:15 AM | marketbeat.com

Scilex Holding Company (Nasdaq: SCLX) Announces Its Majority-Owned Subsidiary, Semnur Pharmaceuticals, Inc. (“Semnur”), and Denali Capital Acquisition Corp. Have Entered ...

August 21, 2025 | theglobeandmail.com

Scilex Subsidiary Semnur Pharma Eyes $20M Private Placement Deal: More Details Inside

August 21, 2025 | msn.com

Scilex Holding Company and Semnur Pharmaceuticals Announce $20 Million Private Placement for SP-102 Clinical Trial and Leadership Transition

August 21, 2025 | quiverquant.comQ

Scilex Holding Company (Nasdaq: SCLX) Announces Its Majority-Owned Subsidiary, Semnur Pharmaceuticals, Inc. (“Semnur”), and Denali Capital Acquisition Corp. Have Entered into a Purchase Agreement with an Investor for a $20 Million Private Placement at $16.00 per share and Jaisim Shah, Scilex's CEO and President, Will be Dedicated to Semnur on a Full Time Basis to Rapidly Advance SP-102 to Regulato

August 21, 2025 | globenewswire.com

Scilex (NASDAQ:SCLX) Releases Earnings Results, Misses Estimates By $2.87 EPS

August 15, 2025 | marketbeat.com

Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral ...

August 15, 2025 | theglobeandmail.com

Scilex Holding Company (Nasdaq: SCLX) Announces Effectiveness of Registration Statement on Form S-4 for the Proposed Business Combination of Denali Capital Acquisition Corp. and Semnur Pharmaceuticals, Inc., a Majority-Owned Subsidiary of Scilex

August 13, 2025 | globenewswire.com

Scilex (SCLX) Expected to Announce Quarterly Earnings on Tuesday

August 6, 2025 | marketbeat.com

Scilex (NASDAQ:SCLX) Stock Price Up 3.7% - Time to Buy?

August 2, 2025 | marketbeat.com

Scilex Holding Co. (SCLX) Stock Price Today - WSJ

July 24, 2025 | wsj.com

SCLX Scilex Holding Company - Seeking Alpha

July 1, 2025 | seekingalpha.com

Scilex Holding Company Announces Deferral of Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in ...

June 25, 2025 | theglobeandmail.com

Scilex Holding Company Announces Deferral of Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from May 2, 2025 to a future date to be determined by the Board

June 23, 2025 | globenewswire.com

Scilex Holding Company Announces Publication on GLOPERBA® Dosing Adjustments in Peer-Review Journal

June 5, 2025 | globenewswire.com

Scilex Holding Stock Price History

June 1, 2025 | investing.com

Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL

May 16, 2025 | globenewswire.com

Scilex adjusts director compensation post-stock split

May 13, 2025 | investing.com

Scilex Holding Company to Present Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL.

May 1, 2025 | globenewswire.com

Scilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price Rule

April 30, 2025 | globenewswire.com

Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 2025 to May 2, 2025

April 22, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

HYPD, CTOR, FATE, and SCLX Company Descriptions

Citius Oncology NASDAQ:CTOR

$2.12 +0.03 (+1.44%)

Closing price 04:00 PM Eastern

Extended Trading

$2.09 -0.03 (-1.37%)

As of 06:43 PM Eastern

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

Fate Therapeutics NASDAQ:FATE

$1.08 -0.04 (-3.57%)

Closing price 04:00 PM Eastern

Extended Trading

$1.10 +0.02 (+1.85%)

As of 07:46 PM Eastern

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Hyperion DeFi NASDAQ:HYPD

$6.63 -0.27 (-3.91%)

As of 04:00 PM Eastern

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

Scilex NASDAQ:SCLX

$18.23 +0.21 (+1.17%)

Closing price 04:00 PM Eastern

Extended Trading

$18.30 +0.07 (+0.41%)

As of 07:45 PM Eastern

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time